Castleman Disease with MDM2/CDK4 Protein Expression: a Potential Mimic of Inflammatory Variant of Liposarcoma with Significant Consequences. (October 2022)

• Record Type: Journal Article
• Authors: Georgantzoglou, Natalia; Baker, Michael; Liu, Xiaoying; Kerr, Darcy A.; Linos, Konstantinos
• Is Part Of: International journal of surgical pathology. Volume 30:Number 7(2022)
• Page Start: 753
• Page End: 759
• Publication Date: 2022-10
• Subjects: Castleman disease -- well-differentiated liposarcoma -- dedifferentiated liposarcoma -- inflammatory liposarcoma -- retroperitoneum; Pathology, Surgical -- Periodicals; 617.07
• DOI: 10.1177/10668969221080083
• Languages: English
• ISSNs: 1066-8969

Abstract

Castleman disease is a rare benign lymphoproliferative disorder that includes a spectrum of distinct histopathological entities. The differential diagnosis of Castleman disease is broad and includes lymphomas, HIV-related lymphadenopathy, autoimmune disorders, and inflammatory liposarcoma. When Castleman disease occurs in the retroperitoneum, the distinction from the inflammatory variant of well-differentiated liposarcoma can be very challenging in small biopsies. Herein we report a case of Castleman disease that presented as a retroperitoneal mass and expressed MDM2 and CDK4 by immunohistochemistry. To our knowledge, this is the first report of Castleman disease staining positively for MDM2/CDK4, and it underscores how immunohistochemistry can potentially serve as a pitfall when differentiating this rare entity from retroperitoneal sarcomas.